Practical application of anti-TNF therapy for luminal Crohn's disease

Michael A. Kamm*, Siew C. Ng, Peter De Cruz, Patrick Allen, Stephen B. Hanauer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Anti-tumor necrosis factor (TNF) therapy to treat inflammatory bowel disease has been available for more than a decade. Although extensive data on the outcome of anti-TNF therapy from individual clinical trials and patient cohorts are available, integrated guidance on the best use of such therapy to achieve optimal clinical outcomes when managing patients with luminal Crohn's disease is lacking. This review combines published data to establish practical strategies for anti-TNF therapy with respect to effective and safe timing of introduction, use of concurrent immunosuppressive therapy, dose escalation, managing relapse, changing drugs, pregnancy and breast feeding, and stopping drug treatment.

Original languageEnglish (US)
Pages (from-to)2366-2391
Number of pages26
JournalInflammatory bowel diseases
Issue number11
StatePublished - Nov 2011


  • Crohn's disease
  • adalimumab
  • anti-TNF
  • biologic therapy
  • certolizumab
  • infliximab
  • loss of response
  • remission
  • response

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy


Dive into the research topics of 'Practical application of anti-TNF therapy for luminal Crohn's disease'. Together they form a unique fingerprint.

Cite this